)
)
)
Trillium Medical Ventures
TMV is seeking collaboration opportunities on behalf of former JT Pharma, which was succeeded by Shionogi in December 2025. Our client has a focus on cutting edge, innovative science and global development of orally active, small molecule human therapeutics in the areas of Cardiovascular/Kidney/Skeletal Muscle, Immunology and Neuroscience. We are seeking partnering opportunities, i.e., research and/or development collaborations with leading academic institutions and pharma/biotech.
We are looking for early-stage, first-in-class, orally active, small molecule NCEs that we can develop into therapeutics in the areas of rare diseases or precision medicine in cardiovascular, kidney, neuromuscular, CNS, immunology, and inflammation. We are also interested in novel, first-in-class drug targets and disease-relevant, translational models (in vitro / in vivo).
We are also interested in clinical stage assets for Japan. Areas of interest include Renal, Dermatology, Rheumatology, Gastroenterology
Address
New YorkNew York
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)